BASEL, Switzerland, July 3 -- Cancer Immunology, Immunotherapy, a peer-reviewed journal that says it advances in the field of tumor immunology, published research articles on the following topics in its August 2024 edition (Vol. 73, Issue 8):

* Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma

* Efficacy and safety of immune checkpoint inhibitors in solid tumor patients combined with chronic coronary syndromes or . . .

Click here for more information about our products